244 related articles for article (PubMed ID: 24916699)
1. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival.
Hu CY; Mohtat D; Yu Y; Ko YA; Shenoy N; Bhattacharya S; Izquierdo MC; Park AS; Giricz O; Vallumsetla N; Gundabolu K; Ware K; Bhagat TD; Suzuki M; Pullman J; Liu XS; Greally JM; Susztak K; Verma A
Clin Cancer Res; 2014 Aug; 20(16):4349-60. PubMed ID: 24916699
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide promoter methylome of small renal masses.
Ibragimova I; Slifker MJ; Maradeo ME; Banumathy G; Dulaimi E; Uzzo RG; Cairns P
PLoS One; 2013; 8(10):e77309. PubMed ID: 24204800
[TBL] [Abstract][Full Text] [Related]
3. Aberrant Methylation of the 1p36 Tumor Suppressor Gene RIZ1 in Renal Cell Carcinoma.
Ge P; Yu X; Wang ZC; Lin J
Asian Pac J Cancer Prev; 2015; 16(9):4071-5. PubMed ID: 25987089
[TBL] [Abstract][Full Text] [Related]
4. Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
Urakami S; Shiina H; Enokida H; Hirata H; Kawamoto K; Kawakami T; Kikuno N; Tanaka Y; Majid S; Nakagawa M; Igawa M; Dahiya R
Clin Cancer Res; 2006 Dec; 12(23):6989-97. PubMed ID: 17145819
[TBL] [Abstract][Full Text] [Related]
5. DNA Methylation Signature Reveals Cell Ontogeny of Renal Cell Carcinomas.
Malouf GG; Su X; Zhang J; Creighton CJ; Ho TH; Lu Y; Raynal NJ; Karam JA; Tamboli P; Allanick F; Mouawad R; Spano JP; Khayat D; Wood CG; Jelinek J; Tannir NM
Clin Cancer Res; 2016 Dec; 22(24):6236-6246. PubMed ID: 27256309
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of bone morphogenetic protein 2 may predict clinical outcome and poor overall survival for renal cell carcinoma through epigenetic pathways.
Mitsui Y; Hirata H; Arichi N; Hiraki M; Yasumoto H; Chang I; Fukuhara S; Yamamura S; Shahryari V; Deng G; Saini S; Majid S; Dahiya R; Tanaka Y; Shiina H
Oncotarget; 2015 Apr; 6(11):9577-91. PubMed ID: 25797254
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of promoter CpG island methylation of obesity-related genes in patients with nonmetastatic renal cell carcinoma.
Mendoza-Pérez J; Gu J; Herrera LA; Tannir NM; Zhang S; Matin S; Karam JA; Wood CG; Wu X
Cancer; 2017 Sep; 123(18):3617-3627. PubMed ID: 28543182
[TBL] [Abstract][Full Text] [Related]
8. The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.
Du Z; Li L; Huang X; Jin J; Huang S; Zhang Q; Tao Q
Oncotarget; 2016 Apr; 7(16):21618-30. PubMed ID: 26943038
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation of the SLC16A3 promoter regulates expression of the human lactate transporter MCT4 in renal cancer with consequences for clinical outcome.
Fisel P; Kruck S; Winter S; Bedke J; Hennenlotter J; Nies AT; Scharpf M; Fend F; Stenzl A; Schwab M; Schaeffeler E
Clin Cancer Res; 2013 Sep; 19(18):5170-81. PubMed ID: 23881922
[TBL] [Abstract][Full Text] [Related]
10. Genetic and epigenetic alterations during renal carcinogenesis.
Arai E; Kanai Y
Int J Clin Exp Pathol; 2010 Dec; 4(1):58-73. PubMed ID: 21228928
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel target genes by an epigenetic reactivation screen of renal cancer.
Ibanez de Caceres I; Dulaimi E; Hoffman AM; Al-Saleem T; Uzzo RG; Cairns P
Cancer Res; 2006 May; 66(10):5021-8. PubMed ID: 16707423
[TBL] [Abstract][Full Text] [Related]
13. Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma.
Breault JE; Shiina H; Igawa M; Ribeiro-Filho LA; Deguchi M; Enokida H; Urakami S; Terashima M; Nakagawa M; Kane CJ; Carroll PR; Dahiya R
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):557-64. PubMed ID: 15701841
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation associates with survival in non-metastatic clear cell renal cell carcinoma.
Evelönn EA; Landfors M; Haider Z; Köhn L; Ljungberg B; Roos G; Degerman S
BMC Cancer; 2019 Jan; 19(1):65. PubMed ID: 30642274
[TBL] [Abstract][Full Text] [Related]
15. Novel prognostic prediction model constructed through machine learning on the basis of methylation-driven genes in kidney renal clear cell carcinoma.
Tang W; Cao Y; Ma X
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32633782
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA Kidney Renal Clear Cell Carcinoma (KIRC) project.
Ricketts CJ; Hill VK; Linehan WM
PLoS One; 2014; 9(1):e85621. PubMed ID: 24454902
[TBL] [Abstract][Full Text] [Related]
17. GATA5 CpG island hypermethylation is an independent predictor for poor clinical outcome in renal cell carcinoma.
Peters I; Gebauer K; Dubrowinskaja N; Atschekzei F; Kramer MW; Hennenlotter J; Tezval H; Abbas M; Scherer R; Merseburger AS; Stenzl A; Kuczyk MA; Serth J
Oncol Rep; 2014 Apr; 31(4):1523-30. PubMed ID: 24549248
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation and histone modifications cause silencing of Wnt antagonist gene in human renal cell carcinoma cell lines.
Kawamoto K; Hirata H; Kikuno N; Tanaka Y; Nakagawa M; Dahiya R
Int J Cancer; 2008 Aug; 123(3):535-42. PubMed ID: 18404682
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of HOXA11, a novel functional tumor suppressor for renal cell carcinoma, is associated with RCC TNM classification.
Wang L; Cui Y; Sheng J; Yang Y; Kuang G; Fan Y; Jin J; Zhang Q
Oncotarget; 2017 Mar; 8(13):21861-21870. PubMed ID: 28423531
[TBL] [Abstract][Full Text] [Related]
20. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]